eShowcase: ClearTrial 2.0
Web-based dashboard places clinical trial designers squarely in the driver's seat
Web-based dashboard places clinical trial designers squarely in the driver's seat
ClearTrial, LLC (Oakbrook Terrace, IL) has released version 2.0 of its clinical trial operations planning software to help biopharm companies and CROs plan, budget, and optimize the operational design of clinical trials.
The heart of this latest version is a Web-based "dashboard" that offers a view of monthly budgets, accruals forecasts, study metrics, cycle-time dates, costs, and FTE/resource requirements. Also new is support for multiple outsourcing strategies, full-service outsourcing, hybrid studies, staff augmentation, and internal studies.
Other adornments to this version include the ability to compare cost and timelines between internal studies and outsourced ones, as well as assign study tasks to multiple service providers by function or country. Collaborative planning is also now possible between departments, business units, and strategic partners.
ClearTrial 2.0 is a J2EE-compliant, native Web-based application running over an Oracle database.
ClearTrial, LLC, (630) 424-1601, www.cleartrial.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
